|
*Together with |
 | (Nasdaq: ALBT) |
|
Good day, 360! |
Here are our top investing ideas today. These setups look primed! Be the best prepared trader on the Street! |
|
|
AULT - Up over 40% in pre-market after listing its 4 newly renovated hotels for sale for approximately $100 million |
ADXN - Up over 15% in pre after Brain publishes company's positive post-stroke recovery data |
XXII - Up over 8% in in pre after announcing it has initiated a strategic alternatives process for its tobacco assets |
|
*A Message on Behalf of Avalon GloboCare Corp | If you care at all about small stocks forgotten in the "bargain basement," then you need to look this one up immediately: | Avalon GloboCare Corp (Nasdaq: ALBT) | Right now, ALBT is sporting a market cap of around $10M (according to Yahoo!), yet over the last few months, it has developed into a premier genetic testing lab that has generated $14.7M in sales in 2022 with $8M in gross profit! | Does that sound like a value play to you?! | Stop and ask yourself if you think a stock with those kinds of metrics is likely to head higher or lower from here? 🤔 We don't think you need to be a stock analyst to know the answer to that! | Look at some of these stats we pulled directly from ALBT's recent investor presentation from a few weeks ago: | | The company is expanding its services into new states and launching a new product…as has recently divulged a staggering 56% insider ownership of the stock! | You really can't ask for much more confidence from insiders who know the company best than ownership like that. | We really encourage you to take some time today and do your own homework on this stock, such as visiting ALBT's investor page, recent news and reviewing its intriguing roll-up strategy. Remember investing is risky, so take some time to dig in and make your own decisions. | *Sponsored by Winning Media, please see disclosures below |
|
|
|
|
AULT - Up over 40% in pre-market after listing its 4 newly renovated hotels for sale for approximately $100 million |
Ault Alliance (AULT) is a diversified holding company and through its subsidiaries operates through segments such as energy and infrastructure, technology and finance. It offers a real-world goods marketplace, gaming, sweepstakes, consumer electronic solutions, commercial loans, convertible notes, revolving lines of credit and virtual training courses. |
This morning the company announced plans to list for sale its four recently renovated Midwest hotels, the Hilton Garden Inn in Madison West, the Residence Inn in Madison West, the Courtyard in Madison West, and the Hilton Garden Inn in Rockford. |
The Company plans to use the proceeds from the sales of the hotel properties to pay off debt and commit more capital to its core businesses including the crane rental business, the California licensed lender, and data center operations. |
The company plans to sell all four properties through the national real estate brokerage firm, Hospitality Real Estate Counselors ("HREC"), and intends to seek approximately $100 million for the four hotels. |
According to Finviz as of Friday's close, AULT had a market cap of only $5.60 million on 5.37 million shares float. |
The stock is gapping 13% higher in pre-market on the news. |
|
The $1.30 level has acted as support so far in the pre-market. |
Above it, targets to the upside are $1.40, $1.56 and then the pre-market high at $1.60. Beyond that, $2, $3 and $4 come into play. |
Below $1.30, there is potential support at $1.23, $1.14 and a gap to fill at $1.05. |
|
ADXN - Up over 15% in pre after Brain publishes company's positive post-stroke recovery data |
Addex Therapeutics (ADXN) is a development-stage biopharmaceutical company that discovers, develops and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. |
Yesterday, the company announced that its data was published in Brain demonstrating the potential therapeutic role of mGlu5 receptor negative allosteric modulators (NAMs) in facilitating functional recovery following stroke supports the future development of dipraglurant in post-stroke recovery. |
The study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functions and for the first time mGlu5 was linked to post-stroke functional recovery. |
The stock is gapping 15% higher this morning on the news. |
|
The $0.50 area acted as support in the pre-market and will be an important level to watch. |
Above it, targets to the upside are $0.54 and then the pre-market high at $0.5890. Beyond that, $0.67, $0.70 and $0.80 come into play. |
Below $0.50, there is potential support at $0.4836 and a gap to fill at $0.4540. |
|
|
XXII - Up over 8% in in pre after announcing it has initiated a strategic alternatives process for its tobacco assets |
22nd Century Group (XXII) is an agricultural biotechnology company that focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names, and SPECTRUM research cigarettes for use in independent clinical studies. |
This morning, the company announced that it has initiated a process to evaluate strategic alternatives with respect to the Company's tobacco assets. The process will include consideration of a range of strategic, operational and financial transactions and alternatives, such as business combinations, asset sales, licensing agreements, alternate financing strategies and other options. |
The company stated: |
"We believe the current market capitalization of the Company does not appropriately reflect the value of our assets or their long-term potential. After extensive discussion, our Board has determined that the best way to maximize value for shareholders is to comprehensively evaluate the Company's strategic alternatives," said Nora Sullivan, Chair of the Board of 22nd Century. " |
The stock is trading up over 8% in pre-market after the press release. |
|
|
$1.33 is a support level from the pre-market after being an area of prior resistance. |
Above it, targets to the upside are $1.42 and then the pre-market high at $1.45. Beyond that, $2, $2.40, $2.75, $3 and $4 come into play. |
Below $1.33, there is potential support at $1.30 and a gap to fill at $1.26. |
|
|
Economic Calendar |
|
|
P.S. Make sure you text "RAGE" to (888) 404-5747 to get all of our latest HOT STOCK ideas! |
*This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull |
|
|
|
Post a Comment
Post a Comment